联合化疗加或不加硼替佐米治疗新诊断的 T 细胞急性淋巴细胞白血病或 II-IV 期 T 细胞淋巴母细胞淋巴瘤的年轻患者
在新诊断的 T 淋巴细胞白血病 (T-ALL) 和 T 淋巴母细胞淋巴瘤 (T-LLy) 中研究硼替佐米 (NSC# 681239) 对改良增强型 BFM (ABFM) 骨架的 III 期随机试验
This randomized phase III trial compares how well combination chemotherapy works when given with or without bortezomib in treating patients with newly diagnosed T-cell acute lymphoblastic leukemia or stage II-IV T-cell lymphoblastic lymphoma. Bortezomib may help reduce the number of leukemia or lymphoma cells by blocking some of the enzymes needed for cell growth. It may also help chemotherapy work better by making cancer cells more sensitive to the drugs. It is not yet known if giving standard chemotherapy with or without bortezomib is more effective in treating newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
研究概览
地位
条件
干预/治疗
- 药品:Cyclophosphamide
- 药品:Doxorubicin Hydrochloride
- 药品:Doxorubicin
- 药品:Vincristine
- 药品:Vincristine Sulfate
- 药品:Cytarabine
- 药品:Daunorubicin
- 药品:Daunorubicin Hydrochloride
- 药品:Etoposide
- 药品:Ifosfamide
- 辐射:Radiation Therapy
- 药品:Leucovorin Calcium
- 药品:Dexamethasone
- 药品:Pegaspargase
- 药品:Thioguanine
- 药品:Bortezomib
- 药品:Hydrocortisone Sodium Succinate
- 药品:Mercaptopurine
- 药品:Methotrexate
详细说明
PRIMARY OBJECTIVES:
I. To compare event-free survival (EFS) in patients with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LLy) who are randomized to a modified augmented Berlin-Frankfurt-Munster (ABFM) backbone versus bortezomib plus the modified ABFM backbone.
SECONDARY OBJECTIVES:
I. To determine the safety and feasibility of modifying standard therapy for T-ALL and T-LLy based on the results of UKALL 2003, which includes a dexamethasone-based induction, additional doses of pegaspargase (PEG-ASP) during induction and delayed intensification (DI), and dexamethasone pulses during maintenance therapy.
II. To determine if prophylactic (presymptomatic) cranial radiation therapy (CRT) can be safely and effectively eliminated in the 85-90% of T-ALL patients classified as standard or intermediate risk.
III. To determine the proportion of end of consolidation (EOC) minimal residual disease (MRD) >= 0.1% T-ALL patients who become MRD negative (undetectable by flow cytometry) after intensification of chemotherapy, using three high risk (HR) BFM blocks, and to compare EFS between the patients who become MRD negative after the three HR BFM blocks and continue on chemotherapy with those who continue to have detectable MRD and are eligible for other treatment strategies, including hematopoietic stem cell transplant (HSCT).
IV. To compare the EFS between very high risk (induction failure) T-LLy patients treated with HR BFM intensification blocks who have partial or complete response (PR or CR) with those who do not respond (NR).
CORRELATIVE OBJECTIVES:
I. To investigate the prognostic significance of day 29 bone marrow (BM) MRD in T-LLy patients.
II. To determine if protein expression patterns can predict bortezomib response and drug resistance in T-ALL.
III. To analyze and target relevant signaling pathways in T-ALL blasts, focusing on early T cell precursor (ETP) acute lymphoblastic leukemia (ALL).
OUTLINE: Patients are randomized to 1 of 2 treatment arms. Patients are risk assigned based on data from end of induction and/or consolidation therapy; this then modifies the subsequent therapy received.
T-ALL Risk Group Definitions:
Standard Risk (SR): CNS1*, lumbar puncture prior to steroid therapy (not steroid pretreated), Day 29 (end of induction) bone marrow M1, Day 29 bone marrow minimal residual disease (MRD) <=0.01%, no testicular leukemia at diagnosis.
Intermediate Risk (IR): Not SR or VHR.
Very High Risk (VHR): M3 marrow at Day 29 and/or end of consolidation (EOC) MRD >=0.1%.
*CNS2 and CNS3 cannot be SR and are assigned to IR or VHR based on marrow response.
T-LL Risk Group Definitions:
Standard Risk (SR): CNS1*, MRD at diagnosis <1% in bone marrow, lumbar puncture prior to steroid therapy (not steroid pretreated), Day 29 (end of induction) complete response (CR) or partial response (PR).
Intermediate Risk (IR): Not SR or VHR.
Very High Risk (VHR): Stable Disease (SD)/No response (NR) at Day 29 (End of Induction).
*CNS2 and CNS3 cannot be SR and are assigned to IR or VHR based on radiographic response.
ARM A INDUCTION: Patients receive cytarabine intrathecally (IT) at time of diagnostic lumbar puncture (if within 72 hours from start of protocol therapy) OR day 1; vincristine sulfate intravenously (IV) over 1 minute on days 1, 8, 15, and 22; dexamethasone orally (PO) twice daily (BID) on days 1-28 (no taper); daunorubicin hydrochloride IV over 1-15 minutes on days 1, 8, 15, and 22; pegaspargase IV over 1-2 hours on days 4 and 18; and methotrexate IT on days 8 and 29 (and on days 15 and 22 for central nervous system 3 involvement [CNS3] T-ALL patients).
ARM A CONSOLIDATION: Beginning on day 36 from Induction, patients receive methotrexate IT on days 1, 8, 15, and 22 (days 1 and 8 only for CNS3 T-ALL or CNS3 T-LLy patients); cyclophosphamide IV over 30-60 minutes on days 1 and 29; cytarabine IV over 1-30 minutes or subcutaneously (SC) on days 1-4, 8-11, 29-32, and 36-39; mercaptopurine PO once daily (QD) on days 1-14 and 29-42; pegaspargase IV over 1-2 hours on days 15 and 43; and vincristine sulfate IV on days 15, 22, 43, and 50. Patients with persistent testicular disease undergo radiation therapy.
Patients are then assigned to subsequent therapy according to risk assignment. Patients with standard risk (SR) disease receive Interim Maintenance with Capizzi methotrexate (CMTX); patients with intermediate risk (IR) disease receive Interim Maintenance with high-dose methotrexate (HDMTX), Delayed Intensification, and then Interim Maintenance with CMTX; and patients with very high risk (VHR) disease receive 3 HR Intensification Blocks, Delayed Intensification, and then Interim Maintenance with CMTX.
ARM A CMTX INTERIM MAINTENANCE: Patients receive vincristine sulfate IV over 1 minute on days 1, 11, 21, 31, and 41; methotrexate IV over 2-5 minutes (undiluted) or 10-15 minutes (diluted) on days 1, 11, 21, 31, and 41; pegaspargase IV over 1-2 hours on days 2 and 22; and methotrexate IT on days 1 and 31. The next course (based on risk assignment) begins on day 57 or when blood counts recover (whichever occurs later).
ARM A DELAYED INTENSIFICATION: Patients receive vincristine sulfate IV over 1 minute on days 1, 8, 15, 43, and 50; dexamethasone PO BID or IV on days 1-7 and 15-21; doxorubicin hydrochloride IV over 15 minutes on days, 1, 8, and 15; pegaspargase IV over 1-2 hours on days 4, 18, and 43; methotrexate IT on days 1, 29, and 36; cyclophosphamide IV over 30-60 minutes on day 29; cytarabine IV over 1-30 minutes or SC on days 29-32 and 36-39; and thioguanine PO on days 29-42. The next course (based on risk assignment) begins on day 64 or when blood counts recover (whichever occurs later).
ARM A HDMTX INTERIM MAINTENANCE: Patients receive high-dose methotrexate IV over 24 hours on days 1, 15, 29, and 43; leucovorin calcium IV or PO on days 3-4, 17-18, 31-32, and 45-46; vincristine sulfate IV on days 1, 15, 29, and 43; mercaptopurine PO QD on days 1-56; and methotrexate IT on days 1 and 29. The next course (based on randomization assignment) begins on day 57 or when blood counts recover (whichever occurs later).
ARM A INTENSIFICATION BLOCK I: Patients receive dexamethasone IV or PO BID on days 1-5; high-dose methotrexate IV over 24 hours on day 1; leucovorin calcium IV or PO on days 3-4; vincristine sulfate IV on days 1 and 6; cyclophosphamide IV over 1-6 hours on days 2-4; high-dose cytarabine IV over 3 hours every 12 hours on day 5; pegaspargase IV over 1-2 hours on day 6; and triple IT therapy comprising methotrexate IT, hydrocortisone IT, and cytarabine IT on day 1. The next course (Intensification Block II) begins on day 22 or when blood counts recover (whichever occurs later).
ARM A INTENSIFICATION BLOCK II: Patients receive dexamethasone PO BID or IV on days 1-5; high-dose methotrexate IV over 24 hours on day 1; leucovorin calcium PO or IV on days 3-4; vincristine sulfate IV on days 1 and 6; ifosfamide IV over 1 hour every 12 hours on days 2-4; daunorubicin hydrochloride IV over 30 minutes on day 5; pegaspargase IV over 1-2 hours on day 6; and triple IT therapy on day 1 as in Intensification Block I. The next course (Intensification Block III) begins on day 22 or when blood counts recover (whichever occurs later).
ARM A INTENSIFICATION BLOCK III: Patients receive dexamethasone PO BID or IV on days 1-5; high-dose cytarabine IV over 3 hours every 12 hours on days 1-2; etoposide IV over 1-2 hours every 12 hours on days 3-5; pegaspargase IV over 1-2 hours on day 6; and triple IT therapy on day 5 as in Intensification Block I. The next course (based on randomization) begins on day 22 or when blood counts recover (whichever occurs later).
ARM A MAINTENANCE THERAPY: All patients receive vincristine sulfate IV over 1 minute on days 1, 29, and 57; dexamethasone PO BID or IV on days 1-5, 29-33, and 57-61; mercaptopurine PO on days 1-84; methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 (omit day 29 for SR patients during the first 4 cycles); methotrexate IT on day 1 (and day 29 during the first 4 cycles for SR patients and during the first 2 cycles for IR patients). Patients with CNS1-3VHR and CNS2 VHR, and CNS3 IR disease also undergo cranial radiation therapy during the first 4 weeks (cycle 1). Treatment in female patients with T-ALL and patients with T-LLY repeats every 12 weeks for up to 2 years from the start of Interim Maintenance (week 119). Treatment in male patients with T-ALL repeats every 12 weeks for up to 3 years from the start of Interim Maintenance (week 171).
ARM B INDUCTION: Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11(1.3 mg/m^2 per dose); and cytarabine, vincristine sulfate, dexamethasone, daunorubicin hydrochloride, pegaspargase, and methotrexate as in Induction Arm A.
ARM B CONSOLIDATION: Beginning on day 36 from Induction, patients receive methotrexate IT on days 1, 8, 15, and 22 (days 1 and 8 only for CNS3 T-ALL or CNS3 T-LLy patients); cyclophosphamide IV over 30-60 minutes on days 1 and 29; cytarabine IV over 1-30 minutes or subcutaneously (SC) on days 1-4, 8-11, 29-32, and 36-39; mercaptopurine PO once daily (QD) on days 1-14 and 29-42; pegaspargase IV over 1-2 hours on days 15 and 43; and vincristine sulfate IV on days 15, 22, 43, and 50. Patients with persistent testicular disease undergo radiation therapy.
Patients are then assigned to subsequent therapy according to risk assignment. Patients with standard risk (SR) disease receive Interim Maintenance with Capizzi methotrexate (CMTX); patients with intermediate risk (IR) disease receive Interim Maintenance with high-dose methotrexate (HDMTX), Delayed Intensification, and then Interim Maintenance with CMTX; and patients with very high risk (VHR) disease receive 3 HR Intensification Blocks, Delayed Intensification, and then Interim Maintenance with CMTX.
ARM B CMTX INTERIM MAINTENANCE: Patients receive vincristine sulfate IV over 1 minute on days 1, 11, 21, 31, and 41; methotrexate IV over 2-5 minutes (undiluted) or 10-15 minutes (diluted) on days 1, 11, 21, 31, and 41; pegaspargase IV over 1-2 hours on days 2 and 22; and methotrexate IT on days 1 and 31. The next course (based on risk assignment) begins on day 57 or when blood counts recover (whichever occurs later).
ARM B DELAYED INTENSIFICATION: Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 15, and 18 (1.3 mg/m^2 per dose); and vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, methotrexate, cyclophosphamide, cytarabine, and thioguanine as in Delayed Intensification Arm A. The next course (based on risk assignment) begins on day 64 or when blood counts recover (whichever occurs later).
ARM B HDMTX INTERIM MAINTENANCE: Patients receive high-dose methotrexate IV over 24 hours on days 1, 15, 29, and 43; leucovorin calcium IV or PO on days 3-4, 17-18, 31-32, and 45-46; vincristine sulfate IV on days 1, 15, 29, and 43; mercaptopurine PO QD on days 1-56; and methotrexate IT on days 1 and 29. The next course (based on randomization assignment) begins on day 57 or when blood counts recover (whichever occurs later).
ARM B INTENSIFICATION BLOCK I: Patients receive dexamethasone IV or PO BID on days 1-5; high-dose methotrexate IV over 24 hours on day 1; leucovorin calcium IV or PO on days 3-4; vincristine sulfate IV on days 1 and 6; cyclophosphamide IV over 1-6 hours on days 2-4; high-dose cytarabine IV over 3 hours every 12 hours on day 5; pegaspargase IV over 1-2 hours on day 6; and triple IT therapy comprising methotrexate IT, hydrocortisone IT, and cytarabine IT on day 1. The next course (Intensification Block II) begins on day 22 or when blood counts recover (whichever occurs later).
ARM B INTENSIFICATION BLOCK II: Patients receive dexamethasone PO BID or IV on days 1-5; high-dose methotrexate IV over 24 hours on day 1; leucovorin calcium PO or IV on days 3-4; vincristine sulfate IV on days 1 and 6; ifosfamide IV over 1 hour every 12 hours on days 2-4; daunorubicin hydrochloride IV over 30 minutes on day 5; pegaspargase IV over 1-2 hours on day 6; and triple IT therapy on day 1 as in Intensification Block I. The next course (Intensification Block III) begins on day 22 or when blood counts recover (whichever occurs later).
ARM B INTENSIFICATION BLOCK III: Patients receive dexamethasone PO BID or IV on days 1-5; high-dose cytarabine IV over 3 hours every 12 hours on days 1-2; etoposide IV over 1-2 hours every 12 hours on days 3-5; pegaspargase IV over 1-2 hours on day 6; and triple IT therapy on day 5 as in Intensification Block I. The next course (based on randomization) begins on day 22 or when blood counts recover (whichever occurs later).
ARM B MAINTENANCE THERAPY: All patients receive vincristine sulfate IV over 1 minute on days 1, 29, and 57; dexamethasone PO BID or IV on days 1-5, 29-33, and 57-61; mercaptopurine PO on days 1-84; methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 (omit day 29 for SR patients during the first 4 cycles); methotrexate IT on day 1 (and day 29 during the first 4 cycles for SR patients and during the first 2 cycles for IR patients). Patients with CNS1-3VHR and CNS2 VHR, and CNS3 IR disease also undergo cranial radiation therapy during the first 4 weeks (cycle 1). Treatment in female patients with T-ALL and patients with T-LLY repeats every 12 weeks for up to 2 years from the start of Interim Maintenance (week 119). Treatment in male patients with T-ALL repeats every 12 weeks for up to 3 years from the start of Interim Maintenance (week 171).
All treatment continues in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up periodically for up to 10 years.
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
Alberta
-
Calgary、Alberta、加拿大、T3B 6A8
- Alberta Children's Hospital
-
Edmonton、Alberta、加拿大、T6G 2B7
- University of Alberta Hospital
-
-
British Columbia
-
Vancouver、British Columbia、加拿大、V6H 3V4
- British Columbia Children's Hospital
-
-
Manitoba
-
Winnipeg、Manitoba、加拿大、R3E 0V9
- CancerCare Manitoba
-
-
Newfoundland and Labrador
-
St. John's、Newfoundland and Labrador、加拿大、A1B 3V6
- Janeway Child Health Centre
-
-
Nova Scotia
-
Halifax、Nova Scotia、加拿大、B3K 6R8
- IWK Health Centre
-
-
Ontario
-
Hamilton、Ontario、加拿大、L8N 3Z5
- McMaster Children's Hospital at Hamilton Health Sciences
-
Kingston、Ontario、加拿大、K7L 2V7
- Kingston Health Sciences Centre
-
London、Ontario、加拿大、N6A 5W9
- Children's Hospital
-
Ottawa、Ontario、加拿大、K1H 8L1
- Children's Hospital of Eastern Ontario
-
Toronto、Ontario、加拿大、M5G 1X8
- Hospital for Sick Children
-
-
Quebec
-
Montreal、Quebec、加拿大、H3H 1P3
- The Montreal Children's Hospital of the MUHC
-
Montreal、Quebec、加拿大、H3T 1C5
- Centre Hospitalier Universitaire Sainte-Justine
-
-
Saskatchewan
-
Saskatoon、Saskatchewan、加拿大、S7N 4H4
- Saskatoon Cancer Centre
-
-
-
-
-
Christchurch、新西兰、8011
- Christchurch Hospital
-
-
Auckland
-
Grafton、Auckland、新西兰、1145
- Starship Children's Hospital
-
-
-
-
New South Wales
-
Hunter Regional Mail Centre、New South Wales、澳大利亚、2310
- John Hunter Children's Hospital
-
Westmead、New South Wales、澳大利亚、2145
- The Children's Hospital at Westmead
-
-
Queensland
-
South Brisbane、Queensland、澳大利亚、4101
- Queensland Children's Hospital
-
-
South Australia
-
North Adelaide、South Australia、澳大利亚、5006
- Women's and Children's Hospital-Adelaide
-
-
Victoria
-
Clayton、Victoria、澳大利亚、3168
- Monash Medical Center-Clayton Campus
-
Parkville、Victoria、澳大利亚、3052
- Royal Children's Hospital
-
-
Western Australia
-
Perth、Western Australia、澳大利亚、6008
- Princess Margaret Hospital for Children
-
Perth、Western Australia、澳大利亚、6009
- Perth Children's Hospital
-
-
-
-
Alabama
-
Birmingham、Alabama、美国、35233
- Children's Hospital of Alabama
-
Mobile、Alabama、美国、36604
- USA Health Strada Patient Care Center
-
-
Alaska
-
Anchorage、Alaska、美国、99508
- Providence Alaska Medical Center
-
-
Arizona
-
Mesa、Arizona、美国、85202
- Banner Children's at Desert
-
Phoenix、Arizona、美国、85016
- Phoenix Childrens Hospital
-
Tucson、Arizona、美国、85719
- Banner University Medical Center - Tucson
-
-
Arkansas
-
Little Rock、Arkansas、美国、72202-3591
- Arkansas Children's Hospital
-
-
California
-
Downey、California、美国、90242
- Kaiser Permanente Downey Medical Center
-
Duarte、California、美国、91010
- City of Hope Comprehensive Cancer Center
-
Loma Linda、California、美国、92354
- Loma Linda University Medical Center
-
Long Beach、California、美国、90806
- Miller Children's and Women's Hospital Long Beach
-
Los Angeles、California、美国、90048
- Cedars-Sinai Medical Center
-
Los Angeles、California、美国、90027
- Children's Hospital Los Angeles
-
Madera、California、美国、93636
- Valley Children's Hospital
-
Oakland、California、美国、94609
- UCSF Benioff Children's Hospital Oakland
-
Oakland、California、美国、94611
- Kaiser Permanente-Oakland
-
Orange、California、美国、92868
- Children's Hospital of Orange County
-
Palo Alto、California、美国、94304
- Lucile Packard Children's Hospital Stanford University
-
Sacramento、California、美国、95816
- Sutter Medical Center Sacramento
-
Sacramento、California、美国、95817
- University of California Davis Comprehensive Cancer Center
-
San Diego、California、美国、92123
- Rady Children's Hospital - San Diego
-
San Diego、California、美国、92134
- Naval Medical Center -San Diego
-
San Francisco、California、美国、94158
- UCSF Medical Center-Mission Bay
-
Torrance、California、美国、90502
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
-
-
Colorado
-
Aurora、Colorado、美国、80045
- Children's Hospital Colorado
-
Denver、Colorado、美国、80218
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
-
-
Connecticut
-
Hartford、Connecticut、美国、06106
- Connecticut Children's Medical Center
-
New Haven、Connecticut、美国、06520
- Yale University
-
-
Delaware
-
Wilmington、Delaware、美国、19803
- Alfred I duPont Hospital for Children
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20010
- Children's National Medical Center
-
Washington D.C.、District of Columbia、美国、20007
- MedStar Georgetown University Hospital
-
-
Florida
-
Fort Lauderdale、Florida、美国、33316
- Broward Health Medical Center
-
Fort Myers、Florida、美国、33908
- Golisano Children's Hospital of Southwest Florida
-
Gainesville、Florida、美国、32610
- UF Health Cancer Institute - Gainesville
-
Hollywood、Florida、美国、33021
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Jacksonville、Florida、美国、32207
- Nemours Children's Clinic-Jacksonville
-
Miami、Florida、美国、33155
- Nicklaus Children's Hospital
-
Miami、Florida、美国、33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami、Florida、美国、33176
- Miami Cancer Institute
-
Orlando、Florida、美国、32827
- Nemours Children's Hospital
-
Orlando、Florida、美国、32803
- AdventHealth Orlando
-
Orlando、Florida、美国、32806
- Arnold Palmer Hospital for Children
-
Pensacola、Florida、美国、32504
- Nemours Children's Clinic - Pensacola
-
St. Petersburg、Florida、美国、33701
- Johns Hopkins All Children's Hospital
-
Tampa、Florida、美国、33606
- Tampa General Hospital
-
Tampa、Florida、美国、33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
West Palm Beach、Florida、美国、33407
- Saint Mary's Medical Center
-
-
Georgia
-
Atlanta、Georgia、美国、30329
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Augusta、Georgia、美国、30912
- Augusta University Medical Center
-
Savannah、Georgia、美国、31404
- Memorial Health University Medical Center
-
-
Hawaii
-
Honolulu、Hawaii、美国、96826
- Kapiolani Medical Center for Women and Children
-
-
Idaho
-
Boise、Idaho、美国、83712
- Saint Luke's Cancer Institute - Boise
-
-
Illinois
-
Chicago、Illinois、美国、60637
- University of Chicago Comprehensive Cancer Center
-
Chicago、Illinois、美国、60612
- University of Illinois
-
Chicago、Illinois、美国、60611
- Lurie Children's Hospital-Chicago
-
Maywood、Illinois、美国、60153
- Loyola University Medical Center
-
Oak Lawn、Illinois、美国、60453
- Advocate Children's Hospital-Oak Lawn
-
Park Ridge、Illinois、美国、60068
- Advocate Children's Hospital-Park Ridge
-
Peoria、Illinois、美国、61637
- OSF Children's Hospital of Illinois
-
Springfield、Illinois、美国、62702
- Southern Illinois University School of Medicine
-
-
Indiana
-
Indianapolis、Indiana、美国、46202
- Riley Hospital for Children
-
Indianapolis、Indiana、美国、46260
- Ascension Saint Vincent Indianapolis Hospital
-
-
Iowa
-
Des Moines、Iowa、美国、50309
- Blank Children's Hospital
-
Iowa City、Iowa、美国、52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Kentucky
-
Lexington、Kentucky、美国、40536
- University of Kentucky/Markey Cancer Center
-
Louisville、Kentucky、美国、40202
- Norton Children's Hospital
-
-
Louisiana
-
New Orleans、Louisiana、美国、70121
- Ochsner Medical Center Jefferson
-
New Orleans、Louisiana、美国、70118
- Children's Hospital New Orleans
-
-
Maine
-
Bangor、Maine、美国、04401
- Eastern Maine Medical Center
-
Scarborough、Maine、美国、04074
- Maine Children's Cancer Program
-
-
Maryland
-
Baltimore、Maryland、美国、21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore、Maryland、美国、21215
- Sinai Hospital of Baltimore
-
Baltimore、Maryland、美国、21201
- University of Maryland/Greenebaum Cancer Center
-
Bethesda、Maryland、美国、20889-5600
- Walter Reed National Military Medical Center
-
-
Massachusetts
-
Boston、Massachusetts、美国、02114
- Massachusetts General Hospital Cancer Center
-
Boston、Massachusetts、美国、02111
- Tufts Children's Hospital
-
Springfield、Massachusetts、美国、01199
- Baystate Medical Center
-
Worcester、Massachusetts、美国、01655
- UMass Memorial Medical Center - University Campus
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
- C S Mott Children's Hospital
-
Detroit、Michigan、美国、48201
- Wayne State University/Karmanos Cancer Institute
-
Detroit、Michigan、美国、48236
- Henry Ford Health Saint John Hospital
-
East Lansing、Michigan、美国、48823
- Michigan State University
-
Flint、Michigan、美国、48503
- Hurley Medical Center
-
Grand Rapids、Michigan、美国、49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Grand Rapids、Michigan、美国、49503
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Kalamazoo、Michigan、美国、49007
- West Michigan Cancer Center
-
Kalamazoo、Michigan、美国、49007
- Bronson Methodist Hospital
-
Royal Oak、Michigan、美国、48073
- Corewell Health Children's
-
-
Minnesota
-
Minneapolis、Minnesota、美国、55404
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Minneapolis、Minnesota、美国、55455
- University of Minnesota/Masonic Cancer Center
-
Rochester、Minnesota、美国、55905
- Mayo Clinic in Rochester
-
-
Mississippi
-
Jackson、Mississippi、美国、39216
- University of Mississippi Medical Center
-
-
Missouri
-
Columbia、Missouri、美国、65212
- University of Missouri Children's Hospital
-
Kansas City、Missouri、美国、64108
- Children's Mercy Hospitals and Clinics
-
St Louis、Missouri、美国、63110
- Washington University School of Medicine
-
St Louis、Missouri、美国、63141
- Mercy Hospital Saint Louis
-
St Louis、Missouri、美国、63104
- Cardinal Glennon Children's Medical Center
-
-
Nebraska
-
Omaha、Nebraska、美国、68198
- University of Nebraska Medical Center
-
Omaha、Nebraska、美国、68114
- Children's Hospital and Medical Center of Omaha
-
-
Nevada
-
Las Vegas、Nevada、美国、89144
- Summerlin Hospital Medical Center
-
Las Vegas、Nevada、美国、89109
- Sunrise Hospital and Medical Center
-
Las Vegas、Nevada、美国、89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas、Nevada、美国、89102
- University Medical Center of Southern Nevada
-
-
New Hampshire
-
Lebanon、New Hampshire、美国、03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Hackensack、New Jersey、美国、07601
- Hackensack University Medical Center
-
Morristown、New Jersey、美国、07960
- Morristown Medical Center
-
New Brunswick、New Jersey、美国、08901
- Saint Peter's University Hospital
-
New Brunswick、New Jersey、美国、08903
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Newark、New Jersey、美国、07112
- Newark Beth Israel Medical Center
-
Paterson、New Jersey、美国、07503
- Saint Joseph's Regional Medical Center
-
-
New Mexico
-
Albuquerque、New Mexico、美国、87106
- University of New Mexico Cancer Center
-
-
New York
-
Albany、New York、美国、12208
- Albany Medical Center
-
Buffalo、New York、美国、14263
- Roswell Park Cancer Institute
-
Mineola、New York、美国、11501
- NYU Langone Hospital - Long Island
-
New Hyde Park、New York、美国、11040
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
New York、New York、美国、10029
- Mount Sinai Hospital
-
New York、New York、美国、10065
- NYP/Weill Cornell Medical Center
-
New York、New York、美国、10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester、New York、美国、14642
- University of Rochester
-
Stony Brook、New York、美国、11794
- Stony Brook University Medical Center
-
Syracuse、New York、美国、13210
- State University of New York Upstate Medical University
-
The Bronx、New York、美国、10467
- Montefiore Medical Center - Moses Campus
-
Valhalla、New York、美国、10595
- New York Medical College
-
-
North Carolina
-
Asheville、North Carolina、美国、28801
- Mission Hospital
-
Chapel Hill、North Carolina、美国、27599
- UNC Lineberger Comprehensive Cancer Center
-
Charlotte、North Carolina、美国、28203
- Carolinas Medical Center/Levine Cancer Institute
-
Charlotte、North Carolina、美国、28204
- Novant Health Presbyterian Medical Center
-
Durham、North Carolina、美国、27710
- Duke University Medical Center
-
Greenville、North Carolina、美国、27834
- East Carolina University
-
Winston-Salem、North Carolina、美国、27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Fargo、North Dakota、美国、58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron、Ohio、美国、44308
- Children's Hospital Medical Center of Akron
-
Cincinnati、Ohio、美国、45229
- Cincinnati Children's Hospital Medical Center
-
Cleveland、Ohio、美国、44195
- Cleveland Clinic Foundation
-
Cleveland、Ohio、美国、44106
- Rainbow Babies and Childrens Hospital
-
Columbus、Ohio、美国、43205
- Nationwide Children's Hospital
-
Dayton、Ohio、美国、45404
- Dayton Children's Hospital
-
Toledo、Ohio、美国、43606
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
Toledo、Ohio、美国、43608
- Mercy Children's Hospital
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland、Oregon、美国、97239
- Oregon Health and Science University
-
Portland、Oregon、美国、97227
- Legacy Emanuel Children's Hospital
-
-
Pennsylvania
-
Allentown、Pennsylvania、美国、18103
- Lehigh Valley Hospital-Cedar Crest
-
Bethlehem、Pennsylvania、美国、18017
- Lehigh Valley Hospital - Muhlenberg
-
Danville、Pennsylvania、美国、17822
- Geisinger Medical Center
-
Hershey、Pennsylvania、美国、17033
- Penn State Children's Hospital
-
Philadelphia、Pennsylvania、美国、19104
- Children's Hospital of Philadelphia
-
Philadelphia、Pennsylvania、美国、19134
- Saint Christopher's Hospital for Children
-
Pittsburgh、Pennsylvania、美国、15224
- Children's Hospital of Pittsburgh of UPMC
-
-
South Carolina
-
Charleston、South Carolina、美国、29425
- Medical University of South Carolina
-
Columbia、South Carolina、美国、29203
- Prisma Health Richland Hospital
-
Greenville、South Carolina、美国、29605
- BI-LO Charities Children's Cancer Center
-
-
South Dakota
-
Sioux Falls、South Dakota、美国、57117-5134
- Sanford USD Medical Center - Sioux Falls
-
-
Tennessee
-
Chattanooga、Tennessee、美国、37403
- T C Thompson Children's Hospital
-
Knoxville、Tennessee、美国、37916
- East Tennessee Childrens Hospital
-
Nashville、Tennessee、美国、37232
- Vanderbilt University/Ingram Cancer Center
-
Nashville、Tennessee、美国、37203
- The Children's Hospital at TriStar Centennial
-
-
Texas
-
Austin、Texas、美国、78723
- Dell Children's Medical Center of Central Texas
-
Corpus Christi、Texas、美国、78411
- Driscoll Children's Hospital
-
Dallas、Texas、美国、75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Dallas、Texas、美国、75230
- Medical City Dallas Hospital
-
El Paso、Texas、美国、79905
- El Paso Children's Hospital
-
Fort Worth、Texas、美国、76104
- Cook Children's Medical Center
-
Houston、Texas、美国、77030
- UT MD Anderson Cancer Center
-
Houston、Texas、美国、77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Lubbock、Texas、美国、79410
- Covenant Children's Hospital
-
Lubbock、Texas、美国、79415
- UMC Cancer Center / UMC Health System
-
San Antonio、Texas、美国、78229
- University of Texas Health Science Center at San Antonio
-
San Antonio、Texas、美国、78207
- Children's Hospital of San Antonio
-
San Antonio、Texas、美国、78229
- Methodist Children's Hospital of South Texas
-
-
Utah
-
Salt Lake City、Utah、美国、84113
- Primary Children's Hospital
-
-
Vermont
-
Burlington、Vermont、美国、05405
- University of Vermont and State Agricultural College
-
-
Virginia
-
Charlottesville、Virginia、美国、22908
- University of Virginia Cancer Center
-
Falls Church、Virginia、美国、22042
- Inova Fairfax Hospital
-
Norfolk、Virginia、美国、23507
- Children's Hospital of The King's Daughters
-
Portsmouth、Virginia、美国、23708-2197
- Naval Medical Center - Portsmouth
-
Richmond、Virginia、美国、23298
- VCU Massey Comprehensive Cancer Center
-
Roanoke、Virginia、美国、24014
- Carilion Children's
-
-
Washington
-
Seattle、Washington、美国、98105
- Seattle Children's Hospital
-
Spokane、Washington、美国、99204
- Providence Sacred Heart Medical Center and Children's Hospital
-
Tacoma、Washington、美国、98405
- Mary Bridge Children's Hospital and Health Center
-
Tacoma、Washington、美国、98431
- Madigan Army Medical Center
-
-
West Virginia
-
Charleston、West Virginia、美国、25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
Morgantown、West Virginia、美国、26506
- West Virginia University Healthcare
-
-
Wisconsin
-
Green Bay、Wisconsin、美国、54301
- Saint Vincent Hospital Cancer Center Green Bay
-
Madison、Wisconsin、美国、53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marshfield、Wisconsin、美国、54449
- Marshfield Medical Center-Marshfield
-
Milwaukee、Wisconsin、美国、53226
- Children's Hospital of Wisconsin
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
T-ALL: T-ALL patients must be enrolled on AALL08B1 or Project:EveryChild (APEC14B1, if open for the classification of ALL patients) prior to treatment and enrollment on AALL1231
-
All patients must be > 1 and < 31 years of age
-
Patients must have newly diagnosed T-lymphoblastic leukemia (T-ALL) or T-lymphoblastic lymphoma (T-LLy) stages II-IV
- Note: a diagnosis of T-ALL is established when leukemic blasts lack myeloperoxidase or evidence of B-lineage derivation (cluster of differentiation [CD]19/CD22/CD20), and express either surface or cytoplasmic CD3 or two or more of the antigens CD8, CD7, CD5, CD4, CD2 or CD1a, and are present either in peripheral blood or > 25% in the bone marrow; if surface CD3 is expressed on all leukemic cells, additional markers of immaturity, including terminal deoxynucleotidyl transferase (TdT), CD34 or CD99 will be assessed for expression; cases with uncertain expression will receive additional review within the appropriate Children's Oncology Group (COG) reference laboratory
- For T-LLy patients with tissue available for flow cytometry, the criterion for diagnosis should be analogous to T-ALL; for tissue processed by other means (i.e. paraffin blocks), the methodology and criteria for immunophenotypic analysis to establish the diagnosis of T-LLy defined by the submitting institution will be accepted
-
All patients and/or their parents or legal guardians must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines
Exclusion Criteria:
-
Patients must not have received any cytotoxic chemotherapy for either the current diagnosis of T-ALL, T-L-Ly or for any cancer diagnosis prior to the initiation of protocol therapy on AALL1231, with the exception of:
-
Steroid pretreatment: prednisone or methylprednisolone for =< 120 hours (5 days) in the 7 days prior to initiating induction chemotherapy or for =< 336 hours (14 days) in the 28 days prior to initiating induction chemotherapy; prior exposure to ANY steroids that occurred > 28 days before the initiation of protocol therapy does not affect eligibility; the dose of prednisone or methylprednisolone does not affect eligibility
-
Intrathecal cytarabine (the CNS status must be determined based on a sample obtained prior to administration of any systemic or intrathecal chemotherapy, except for steroid pretreatment) system chemotherapy must begin with 72 hours of this IT therapy; or
-
Pretreatment with hydroxyurea; or
-
600 cGy of chest irradiation, if medically necessary
- Pre-treatment with dexamethasone in the 28 days prior to initiation of protocol therapy is not allowed with the exception of a single dose of dexamethasone use during sedation to prevent or treat airway edema; inhalation steroids and topical steroids are not considered pretreatment
-
-
Pre-existing >= grade 2 sensory or motor peripheral neurotoxicity
-
Uncontrolled seizure disorder
-
Diagnosis of Down syndrome (Trisomy 21)
-
Patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs; a pregnancy test is required for female patients of childbearing potential
-
Lactating females who plan to breastfeed
-
Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation
-
Patient has hypersensitivity to bortezomib, boron, or mannitol
-
Serious medical or psychiatric illness likely to interfere with participation in this clinical study
-
Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and within 30 days of any dose of bortezomib
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Arm A (combination chemotherapy)
Patients receive combination chemotherapy without bortezomib. See Detailed Description. |
Given IV
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Given IT, IV, or SC
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Undergo radiation therapy
其他名称:
Given PO or IV
其他名称:
Given PO or IV
其他名称:
Given IV
其他名称:
Given PO
其他名称:
Given IT
其他名称:
Give PO
其他名称:
Given IT, IV, or PO
其他名称:
|
|
实验性的:Arm B (combination chemotherapy, bortezomib)
Patients receive combination chemotherapy with bortezomib (4 doses at 1.3 mg/m^2 during Induction and 4 doses at 1.3 mg/m^2 during Delayed Intensification). See Detailed Description. |
Given IV
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Given IT, IV, or SC
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Undergo radiation therapy
其他名称:
Given PO or IV
其他名称:
Given PO or IV
其他名称:
Given IV
其他名称:
Given PO
其他名称:
Given IV
其他名称:
Given IT
其他名称:
Give PO
其他名称:
Given IT, IV, or PO
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Event-free Survival (EFS) for Modified Augmented Berlin-Frankfurt-Munster Backbone With or Without Bortezomib in All Randomized Patients
大体时间:3 years
|
EFS is calculated as time from randomization at study entry to first event (induction failure, induction death, relapse, second malignancy, remission death) or date of last contact. Three-year EFS rates will be calculated for both groups. |
3 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Toxicity Rates Associated With Modified Standard Therapy, Including Dexamethasone and Additional Pegaspargase
大体时间:3 years from start of therapy by patient
|
Percentage of patients who experienced Grade 3 or higher Toxicity Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 |
3 years from start of therapy by patient
|
|
EFS for Standard (SR) and Intermediate Risk (IR) T-ALL Patients on the Non-bortezomib Containing Arm on This Study (no Cranial Radiation Therapy [CRT]) and Similar Patients on AALL0434 (Received CRT)
大体时间:3 years
|
EFS is calculated as time from randomization at study entry to first event (induction failure, induction death, relapse, second malignancy, remission death) or date of last contact. |
3 years
|
|
Cumulative Incidence Rates of Isolated Central Nervous System (CNS) Relapse for SR and IR T-ALL Patients on the Non-bortezomib Containing Arm on This Study (no CRT) and Similar Patients on AALL0434 (Receive CRT)
大体时间:3 years
|
Cumulative incidence of isolated CNS relapse adjusting for competing risks using the method of: Gray R, A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1141:1154, 1988 |
3 years
|
|
EFS for Very High Risk (VHR) T-ALL Patients Treated With High Risk (HR) Berlin-Frankfurt-Munster (BFM) Intensification Blocks Who Become Minimal Residual Disease (MRD) Negative and Those Who Remain MRD Positive at the End of HR Block 3
大体时间:3 years
|
EFS will be calculated as time from the end of the three high-risk blocks of therapy to first event (relapse, second malignancy, remission death) or date of last contact. |
3 years
|
|
EFS for Very High Risk (VHR) T-LLy Patients Treated With HR Berlin-Frankfurt-Munster (BFM) Intensification Blocks Who Have Complete or Partial Remission and Those Who do Not Respond
大体时间:3 years
|
EFS for very high risk (VHR) T-LLy patients treated with HR Berlin-Frankfurt-Munster (BFM) intensification blocks who have complete or partial remission and those who do not respond |
3 years
|
合作者和调查者
调查人员
- 首席研究员:David T Teachey、Children's Oncology Group
出版物和有用的链接
一般刊物
- Teachey DT, Devidas M, Wood BL, Chen Z, Hayashi RJ, Hermiston ML, Annett RD, Archer JH, Asselin BL, August KJ, Cho SY, Dunsmore KP, Fisher BT, Freedman JL, Galardy PJ, Harker-Murray P, Horton TM, Jaju AI, Lam A, Messinger YH, Miles RR, Okada M, Patel SI, Schafer ES, Schechter T, Singh N, Steele AC, Sulis ML, Vargas SL, Winter SS, Wood C, Zweidler-McKay P, Bollard CM, Loh ML, Hunger SP, Raetz EA. Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. J Clin Oncol. 2022 Jul 1;40(19):2106-2118. doi: 10.1200/JCO.21.02678. Epub 2022 Mar 10.
- Hayashi RJ, Hermiston ML, Wood BL, Teachey DT, Devidas M, Chen Z, Annett RD, Asselin BL, August K, Cho S, Dunsmore KP, Freedman JL, Galardy PJ, Harker-Murray P, Horton TM, Jaju A, Lam A, Messinger YH, Miles RR, Okada M, Patel S, Schafer ES, Schechter T, Shimano KA, Singh N, Steele A, Sulis ML, Vargas SL, Winter SS, Wood C, Zweidler-McKay PA, Loh ML, Hunger SP, Raetz EA, Bollard CM, Allen CE. MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231. Blood. 2024 May 16;143(20):2053-2058. doi: 10.1182/blood.2023021184.
- Gossai NP, Devidas M, Chen Z, Wood BL, Zweidler-McKay PA, Rabin KR, Loh ML, Raetz EA, Winick NJ, Burke MJ, Carroll AJ, Esiashvili N, Heerema NA, Carroll WL, Hunger SP, Dunsmore KP, Winter SS, Teachey DT. Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children's Oncology Group report. Blood. 2023 Apr 13;141(15):1802-1811. doi: 10.1182/blood.2022018653.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
- 肿瘤
- 免疫系统疾病
- 组织学类型的肿瘤
- 血液病
- 淋巴系统疾病
- 淋巴增生性疾病
- 免疫增生性疾病
- 白血病、淋巴细胞
- 白血病
- 前体细胞淋巴细胞白血病-淋巴瘤
- 半身和淋巴疾病
- 前体 T 细胞淋巴细胞白血病-淋巴瘤
- 荷尔蒙
- 激素、激素替代品和激素拮抗剂
- 硫化合物
- 有机化学品
- 杂环化合物,1形
- 杂环化合物
- 杂环化合物,2环
- 杂环化合物,融合环
- 疗法
- 核酸,核苷酸和核苷
- 碳氢化合物
- 碳氢化合物,循环
- 碳水化合物
- 身体现象
- 生物碱
- Podophyllotoxin
- 四氢乙烯甲烯烃
- 萘
- 多环芳烃
- 碳氢化合物,芳香族
- 多环化合物
- 葡萄糖剂
- 糖苷
- 酶和辅酶
- 吲哚
- 无机化学物质
- 嘌呤
- 胞苷
- 嘧啶核苷
- 嘧啶
- 怀孕
- 怀孕
- 类固醇
- 融合环化合物
- 类固醇,氟化
- 苯衍生物
- 磺酸
- 硫酸
- 磷酰胺芥末
- 氮芥末化合物
- 芥末化合物
- 碳氢化合物,卤素
- 磷酰胺
- 有机磷化合物
- 核苷
- 甲基四氢胶酸盐
- 四氢胶质
- 叶酸
- 翼
- 翼状
- 疗法
- VINCA生物碱
- Secologanin色素生物碱
- 吲哚生物碱
- 吲哚衍生物
- 吲哚王
- 阿拉伯核苷
- 氨基翅目
- 蒽环类动物
- 萘烯
- 氨基糖苷
- 辅酶
- 怀孕
- 怀孕
- 硼酸
- 酸,非羧基
- 酸
- 硼化合物
- 吡嗪
- 11-羟基皮质类固醇
- 羟基皮质类固醇
- 肾上腺皮质激素
- 17-羟基皮质类固醇
- 奥沙嗪
- 苯磺酸盐
- 芳基磺酸盐
- 芳基磺酸
- 亚硫烯基化合物
- 硼替佐米
- 地塞米松
- 甲氨蝶呤
- 环磷酰胺
- 阿糖胞苷
- 依托泊苷
- 亚叶酸
- 阿霉素
- 长春新碱
- 柔红霉素
- 氢化可的松
- 巯基嘌呤
- 硫鸟嘌呤
- 异环磷酰胺
- 羟苯磺酸钙
- 放疗
- 辐射
- 地塞米松21-磷酸盐
- 阿扎硫嘌呤
- 铜
- pegaspargase
- 耳原则
- 乙酸地塞米松
- 氢化可的松半核酸盐
其他研究编号
- NCI-2014-00712
- U10CA180886 (美国 NIH 拨款/合同)
- U10CA098543 (美国 NIH 拨款/合同)
- NCI-2014-00712 (注册表标识符:CTRP (Clinical Trial Reporting Program))
- s14-01925
- AALL1231 (其他标识符:CTEP)
- AALL1231 (其他标识符:Children's Oncology Group)
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.